Compounds > naltrexone

naltrexone and proline

naltrexone has been researched along with proline in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19901 (25.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Legator, MS; Truong, L; Ward, JB1
Blakely, RD; Cohen, SM; Domin, B; Fremeau, RT; Henzi, VA; Miller, JW; Nadler, JV; Shafqat, S; Velaz-Faircloth, M1
Dong, S; Li, M; Ma, G; Zhou, L1
Hussar, DA1

Other Studies

4 other study(ies) available for naltrexone and proline

ArticleYear
Detection of alkylating agents by the analysis of amino acid residues in hemoglobin and urine. 1. The in vivo and in vitro effects of ethyl methanesulfonate, methyl methanesulfonate, hycanthone methanesulfonate, and naltrexone.
    Mutation research, 1978, Volume: 54, Issue:3

    Topics: Alkylating Agents; Amino Acid Sequence; Amino Acids; Animals; Ethyl Methanesulfonate; Hemoglobins; Histidine; Humans; Hycanthone; Male; Methyl Methanesulfonate; Naltrexone; Phenylalanine; Proline; Rats

1978
A novel nonopioid action of enkephalins: competitive inhibition of the mammalian brain high affinity L-proline transporter.
    Molecular pharmacology, 1996, Volume: 49, Issue:6

    Topics: Amino Acid Transport Systems, Neutral; Animals; Brain; Enkephalins; HeLa Cells; Humans; Male; Membrane Transport Modulators; Membrane Transport Proteins; Naltrexone; Proline; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship

1996
Analgesic properties of chimeric peptide based on morphiceptin and PFRTic-amide.
    Regulatory peptides, 2012, Nov-10, Volume: 179, Issue:1-3

    Topics: Analgesia; Analgesics, Opioid; Animals; Arginine; Dose-Response Relationship, Drug; Endorphins; Guinea Pigs; Male; Mice; Morphinans; Naloxone; Naltrexone; Neuropeptides; Opioid Peptides; Proline; Receptors, Neuropeptide; Tetrahydroisoquinolines; Time Factors

2012
New Drugs 2018, part 1.
    Nursing, 2018, Volume: 48, Issue:2

    Topics: Aminoisobutyric Acids; Antibodies, Monoclonal; Antibodies, Neutralizing; Antipyrine; Benzamides; Benzimidazoles; Broadly Neutralizing Antibodies; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Edaravone; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Naltrexone; Natriuretic Peptides; Proline; Pyridines; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration

2018